secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0001493152-24-030145
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TenX Keane shareholders approve business combination with Citius Oncology; redemptions total $49.3M
--------------------------------------------------------------------------------

- All eight proposals approved, including business combination, domestication to Delaware, name change to Citius Oncology, and 15M-share stock incentive plan.
- 4,297,828 shares redeemed at ~$11.46 per share, aggregating $49,265,965 from trust account.
- Eight directors elected to staggered terms: Myron Holubiak, Joel Mayersohn, Dr. Eugene Holuka, Robert Smith, Carol Webb, Suren Dutia, Leonard Mazur, Dennis McGrath.
- Business combination involves Citius Oncology (spin-off from Citius Pharma) merging into TenX; closing conditions still pending.
- Incentive plan authorizes options, SARs, restricted stock, RSUs, and cash awards for employees, directors, and consultants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000149315224030145/0001493152-24-030145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000149315224030145/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer